Azole Derivatives as SHP2 Inhibitors for Disease Treatment
Summary
IRBM S.P.A. has published patent application US20260109699A1 for azole derivatives capable of inhibiting SHP2 phosphatase activity, filed on September 29, 2023 under application number 19114167. The invention covers new chemical compounds and pharmaceutical compositions for treating disorders associated with SHP2 deregulation, with inventors including Alessia Petrocchi, Christian Montalbetti, Romano Di Fabio, Alina Ciammaichella, and Ilaria Rossetti. CPC classifications span C07D 471/20 and multiple A61K therapeutic composition categories.
About this source
USPTO classification C07D covers heterocyclic organic compounds: the chemical core of most small-molecule drugs, including kinase inhibitors, GLP-1 receptor agonists, antibiotics, antivirals, and CNS therapies. Every newly published application in C07D lands in this feed, around 160 a month. Applications publish 18 months after filing, so this feed reveals what medicinal chemistry groups at Pfizer, Novartis, Roche, Shionogi, and others were synthesizing in the prior year and a half. Watch this if you run a medicinal chemistry program, file patent clearance for new drug candidates, scout competitor pipelines before clinical readouts, or track heterocyclic innovation across therapeutic areas.
What changed
IRBM S.P.A. has filed a new USPTO patent application (US20260109699A1) covering azole compounds designed to inhibit SHP2 phosphatase, a protein associated with various diseases when deregulated. The application includes pharmaceutical compositions and methods of synthesis for these compounds. For pharmaceutical companies and researchers developing oncology or precision medicine therapies targeting the RAS/MAPK pathway, this patent represents potential freedom-to-operate considerations. The application is currently in the publication stage and would require separate prosecution before any patent grant.
Archived snapshot
Apr 23, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
AZOLE DERIVATIVES AS SHP2 INHIBITORS
Application US20260109699A1 Kind: A1 Apr 23, 2026
Assignee
IRBM S.P.A.
Inventors
Alessia PETROCCHI, Christian MONTALBETTI, Romano DI FABIO, Alina CIAMMAICHELLA, Ilaria ROSSETTI
Abstract
The present invention relates to new compounds capable of inhibiting the activity of SHP2 phosphatase. Compounds of the invention can be used for the treatment of disorders associated with SHP2 deregulation. The present invention also relates to pharmaceutical compositions containing said compounds and to their method of synthesis.
CPC Classifications
C07D 471/20 A61K 31/166 A61K 31/175 A61K 31/196 A61K 31/198 A61K 31/255 A61K 31/282 A61K 31/417 A61K 31/497 A61K 31/4985 A61K 31/513 A61K 31/675 A61K 31/7008 A61K 33/243 C07D 519/00
Filing Date
2023-09-29
Application No.
19114167
Parties
Related changes
Get daily alerts for USPTO Patent Applications - Organic Chemistry (C07D)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from IRBM.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when USPTO Patent Applications - Organic Chemistry (C07D) publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.